These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35698135)

  • 21. The three-year evolution of Germany's Digital Therapeutics reimbursement program and its path forward.
    Schmidt L; Pawlitzki M; Renard BY; Meuth SG; Masanneck L
    NPJ Digit Med; 2024 May; 7(1):139. PubMed ID: 38789620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evidence of positive care effects by digital health apps-methodological challenges and approaches].
    König IR; Mittermaier M; Sina C; Raspe M; Stais P; Gamstätter T; Stachwitz P; Wolfrum S; Richter JG; Möckel M;
    Inn Med (Heidelb); 2022 Dec; 63(12):1298-1306. PubMed ID: 36279007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One year of digital health applications (DiGA) in Germany - Rheumatologists' perspectives.
    Richter JG; Chehab G; Stachwitz P; Hagen J; Larsen D; Knitza J; Schneider M; Voormann A; Specker C
    Front Med (Lausanne); 2022; 9():1000668. PubMed ID: 36388899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
    Goldhaber-Fiebert JD; Cipriano LE
    Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Digital health applications (DiGA) in medical and psychotherapeutic care. Opportunities and challenges from the perspective of the healthcare providers].
    Gerlinger G; Mangiapane N; Sander J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1213-1219. PubMed ID: 34550412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
    Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
    Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Telemonitoring and eHealth for arterial hypertension : Status quo and perspectives].
    Beger C; Haller H; Limbourg FP
    Internist (Berl); 2021 Mar; 62(3):263-268. PubMed ID: 33580308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. German Pharmaceutical Pricing: Lessons for the United States.
    Rodwin MA; Gerke S
    Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Not one, but many: developing a multi-indication pricing model for medicines in Belgium.
    Maes I; Kok E; De Torck PJ; Mestre-Ferrandiz J; Simoens S
    Front Pharmacol; 2023; 14():1199253. PubMed ID: 37841908
    [No Abstract]   [Full Text] [Related]  

  • 32. [Digitized healthcare in 2030-a possible scenario].
    Brönneke JB; Hagen J; Kircher P; Matthies H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1285-1291. PubMed ID: 34533601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical success factors for creating sustainable digital health applications: A systematic review of the German case.
    Schramm L; Carbon CC
    Digit Health; 2024; 10():20552076241249604. PubMed ID: 38665883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indication-wide drug pricing: Insights from the pharma market.
    Siegmeier F; Büssgen M
    J Pharm Policy Pract; 2022 Aug; 15(1):53. PubMed ID: 36038951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U; Norlin JM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DiGA - A Chance for the German Healthcare System.
    Sauermann S; Herzberg J; Burkert S; Habetha S
    J Eur CME; 2022; 11(1):2014047. PubMed ID: 34992948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S; Niebuhr D; May U; Wasem J
    Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.